Treatment Approaches to Chronic Lymphocytic Leukemia With High-Risk Molecular Features

The clinical course of chronic lymphocytic leukemia (CLL) is highly variable. Over the past decades, several cytogenetic, immunogenetic and molecular features have emerged that identify patients suffering from CLL with high-risk molecular features. These biomarkers can clearly aid prognostication, but may also be capable of predicting the efficacy of various treatment strategies in subgroups of patients. In this narrative review, we discuss treatment approaches to CLL with high-risk molecular features. Specifically, we review and provide a comprehensive overview of clinical trials evaluating the efficacy of chemotherapy, chemoimmunotherapy and novel agent-based treatments in CLL patients with TP53 aberrations, deletion of the long arm of chromosome 11, complex karyotype, unmutated IGHV, B cell receptor stereotypy, and mutations in NOTCH1 or BIRC3. Furthermore, we discuss future pharmaceutical and immunotherapeutic perspectives for CLL with high-risk molecular features, focusing on agents currently under investigation in clinical trials.

• Publication year

  2021

• Venue

  Frontiers in Oncology

• Publication date

  2021-12-09

• Fields of study

  Medicine

• Identifiers
  DOI 10.3389/fonc.2021.780085PMID 34956898PMCID 8695615
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• FIRST RESULTS OF A HEAD‐TO‐HEAD TRIAL OF ACALABRUTINIB VERSUS IBRUTINIB IN PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA

  2021influential reference
• Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study.

  2021cited by this paper
• Safety and efficacy of obinutuzumab alone or with chemotherapy in previously untreated or relapsed/refractory chronic lymphocytic leukaemia patients: Final analysis of the Phase IIIb GREEN study

  2021cited by this paper
• Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, open-label, randomised trial.

  2021cited by this paper
• Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial

  2021cited by this paper
• Clinical Outcomes in Patients with Multi-Hit TP53 Chronic Lymphocytic Leukemia Treated with Ibrutinib

  2021cited by this paper
• Efficacy and Safety of Duvelisib Following Disease Progression on Ofatumumab in Patients with Relapsed/Refractory CLL or SLL in the DUO Crossover Extension Study

  2020cited by this paper
• The effectiveness of ibrutinib in chronic lymphocytic leukaemia: a nationwide, population‐based study in the Netherlands

  2020cited by this paper
• Clinical significance of TP53, BIRC3, ATM and MAPK-ERK genes in chronic lymphocytic leukaemia: data from the randomised UK LRF CLL4 trial

  2020cited by this paper
• Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors.

  2020cited by this paper
• Feasibility and efficacy of CD19-targeted CAR-T cells with concurrent ibrutinib for CLL after ibrutinib failure.

  2020cited by this paper
• Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax.

  2020cited by this paper
• Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial.

  2020influential reference
• Long-Term Outcomes From a Randomized Dose Optimization Study of Chimeric Antigen Receptor Modified T Cells in Relapsed Chronic Lymphocytic Leukemia.

  2020cited by this paper
• Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib: phase 2, single-arm, multicenter study

  2020cited by this paper
• ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia.

  2020influential reference
• Prognostic and predictive role of gene mutations in chronic lymphocytic leukemia: results from the pivotal phase III study COMPLEMENT1

  2020cited by this paper
• Survival continues to increase in chronic lymphocytic leukaemia: a population‐based analysis among 20 468 patients diagnosed in the Netherlands between 1989 and 2016

  2020cited by this paper
• The complex karyotype and chronic lymphocytic leukemia: prognostic value and diagnostic recommendations

  2020cited by this paper
• Zanubrutinib monotherapy for patients with treatment-naïve chronic lymphocytic leukemia and 17p deletion

  2020cited by this paper
• Prognostic and predictive role of gene mutations in chronic lymphocytic leukemia: results from the pivotal phase III study COMPLEMENT1.

  2020cited by this paper
• Zanubrutinib (BGB-3111) plus obinutuzumab in patients with chronic lymphocytic leukemia and follicular lymphoma.

  2020cited by this paper
• Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial

  2020cited by this paper
• Long-Term Follow-Up of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy.

  2020cited by this paper
• The complex karyotype and chronic lymphocytic leukemia. A review of the literature.

  2020cited by this paper
• Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL.

  2020cited by this paper
• Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study

  2020influential reference
• Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial.

  2020cited by this paper
• A phase 1b/2 study of duvelisib in combination with FCR (DFCR) for frontline therapy for younger CLL patients

  2020cited by this paper
• Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results.

  2019cited by this paper
• Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial.

  2019cited by this paper
• Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia.

  2019cited by this paper
• Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study.

  2019cited by this paper
• Prognostic impact of prevalent chronic lymphocytic leukemia stereotyped subsets: analysis within prospective clinical trials of the German CLL Study Group

  2019cited by this paper
• Prognostic impact of prevalent chronic lymphocytic leukemia stereotyped subsets: analysis within prospective clinical trials of the German CLL Study Group (GCLLSG).

  2019cited by this paper
• ELEVATE TN: Phase 3 Study of Acalabrutinib Combined with Obinutuzumab (O) or Alone Vs O Plus Chlorambucil (Clb) in Patients (Pts) with Treatment-Naive Chronic Lymphocytic Leukemia (CLL).

  2019cited by this paper
• Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study

  2019cited by this paper
• Final analysis from RESONATE: Up to six years of follow‐up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma

  2019cited by this paper
• The impact of complex karyotype on the overall survival of patients with relapsed chronic lymphocytic leukemia treated with idelalisib plus rituximab

  2019cited by this paper
• Biological and clinical implications of BIRC3 mutations in chronic lymphocytic leukemia

  2019cited by this paper
• Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia.

  2019influential reference
• Long-Term Studies Assessing Outcomes of Ibrutinib Therapy in Patients With Del(11q) Chronic Lymphocytic Leukemia.

  2019cited by this paper
• Phase 1 study of selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL.

  2019cited by this paper
• Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions.

  2019cited by this paper
• Gain of the short arm of chromosome 2 (2p gain) has a significant role in drug‐resistant chronic lymphocytic leukemia

  2019cited by this paper
• Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables.

  2019cited by this paper
• Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia

  2019cited by this paper
• Safety and tolerability of conditioning chemotherapy followed by CD19-targeted CAR T cells for relapsed/refractory CLL.

  2019cited by this paper
• Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab.

  2019cited by this paper
• European recommendations and quality assurance for cytogenomic analysis of haematological neoplasms

  2019cited by this paper
• Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations, and clinical impact.

  2019cited by this paper
• Allogeneic transplantation in high-risk chronic lymphocytic leukemia: a single-center, intent-to-treat analysis

  2019cited by this paper
• duvelisib (COPIKTRA, Verastem, Inc.) for adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)

  2018cited by this paper
• Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial.

  2018cited by this paper
• Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2

  2018cited by this paper
• Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis

  2018cited by this paper
• High-risk chronic lymphocytic leukemia in the era of pathway inhibitors: integrating molecular and cellular therapies.

  2018cited by this paper
• Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States

  2018cited by this paper
• Clinical implications of cancer gene mutations in patients with chronic lymphocytic leukemia treated with lenalidomide.

  2018cited by this paper
• Autologous CD19-Targeted CAR T Cells in Patients with Residual CLL following Initial Purine Analog-Based Therapy.

  2018cited by this paper
• NOTCH1 Aberrations in Chronic Lymphocytic Leukemia

  2018cited by this paper
• Clonal diversity predicts adverse outcome in chronic lymphocytic leukemia

  2018cited by this paper
• Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma

  2018cited by this paper
• Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience.

  2018cited by this paper
• Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL

  2018influential reference
• How and when I do allogeneic transplant in CLL.

  2018cited by this paper
• iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL.

  2018cited by this paper
• Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia

  2018cited by this paper
• Duvelisib, a novel oral dual inhibitor of PI3K-δ,γ, is clinically active in advanced hematologic malignancies.

  2018cited by this paper
• Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study.

  2018cited by this paper
• Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients.

  2017cited by this paper
• Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL

  2017cited by this paper
• Idelalisib or Placebo in Combination with Bendamustine and Rituximab in Patients with Relapsed/Refractory CLL - Interim Results of a Phase 3 Randomized, Double-blind Placebo-Controlled Trial

  2017cited by this paper
• Clinicopathological features and outcomes of progression of CLL on the BCL2 inhibitor venetoclax.

  2017cited by this paper
• Ibrutinib treatment improves T cell number and function in CLL patients

  2017cited by this paper
• The mutational landscape of chronic lymphocytic leukemia and its impact on prognosis and treatment.

  2017cited by this paper
• Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib.

  2017cited by this paper
• Patients with chronic lymphocytic leukemia and complex karyotype show an adverse outcome even in absence of TP53/ATM FISH deletions

  2017cited by this paper
• Ventricular arrhythmias and sudden death in patients taking ibrutinib.

  2017cited by this paper
• Idelalisib or Placebo in Combination with Bendamustine and Rituximab in Patients with Relapsed/Refractory CLL Interim Results of a Phase 3 Randomized, Double-blind Placebo-Controlled Trial

  2017cited by this paper
• Real‐world results of ibrutinib in relapsed/refractory CLL in France: Early results on a large series of 428 patients

  2017cited by this paper
• Major prognostic value of complex karyotype in addition to TP53 and IGHV mutational status in first‐line chronic lymphocytic leukemia

  2017cited by this paper
• Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia.

  2016cited by this paper
• Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study.

  2016cited by this paper
• Karyotypic complexity rather than chromosome 8 abnormalities aggravates the outcome of chronic lymphocytic leukemia patients with TP53 aberrations

  2016cited by this paper
• An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data.

  2016cited by this paper
• First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial.

  2016cited by this paper
• Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study.

  2016cited by this paper
• Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study.

  2016cited by this paper
• Complex karyotypes and KRAS and POT1 mutations impact outcome in CLL after chlorambucil-based chemotherapy or chemoimmunotherapy.

  2016cited by this paper
• Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial.

  2016cited by this paper
• The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism.

  2016cited by this paper
• Clinical responses with T lymphocytes targeting malignancy-associated κ light chains.

  2016cited by this paper
• Guidelines for genomic array analysis in acquired haematological neoplastic disorders

  2016cited by this paper
• Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease.

  2016cited by this paper
• Lenalidomide treatment and prognostic markers in relapsed or refractory chronic lymphocytic leukemia: data from the prospective, multicenter phase-II CLL-009 trial

  2016cited by this paper
• Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia.

  2016cited by this paper
• Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia.

  2016cited by this paper
• Clinical Practice Recommendations for Use of Allogeneic Hematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation.

  2016cited by this paper
• Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia.

  2016cited by this paper

• CYP3A4 and CYP3A5 Genes in Cyclophosphamide-treated Chronic Lymphocytic Leukemia Patients: A Pharmacogenetics Study.

  2025cites this paper
• Multi-cohort high-dimensional proteomics reveals early risk markers for lymphoid cancer subtypes

  2025cites this paper
• Multi-Cohort High-Dimensional Proteomics Reveals Early Risk Markers for Lymphoid Cancer Subtypes

  2025cites this paper
• Meta-analysis of the efficacy and adverse effects of acalabrutinib in the management of relapsed/refractory chronic lymphocytic leukemia

  2024cites this paper
• BCL-2 and BTK inhibitors for chronic lymphocytic leukemia: current treatments and overcoming resistance

  2024cites this paper
• Chimeric Antigen Receptor T-Cells in Indolent Lymphoma, Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia.

  2023cites this paper
• Cost Effectiveness of Molecular Diagnostic Testing Algorithms for the Treatment Selection of Frontline Ibrutinib for Patients with Chronic Lymphocytic Leukemia in Australia

  2023cites this paper
• Dysregulation of Small Nucleolar RNAs in B-Cell Malignancies

  2022cites this paper
• Reliable one-step assessment of IGHV mutational status and gene mutations in Chronic Lymphocytic Leukemia by capture-based high throughput sequencing

  2022cites this paper